热门资讯> 正文
Tempus AI宣布与Biontech合作
2024-09-04 21:00
- Tempus AI (NASDAQ:TEM) announced a multi-year collaboration with BioNTech SE (NASDAQ:BNTX) which leverages Tempus' multimodal datasets in support of BioNTech’s next-generation oncology pipeline.
- Under this collaboration, Tempus is providing analytical support and computational biology expertise to BioNTech across its comprehensive research and development oncology pipeline.
- Source: Press Release
More on BioNTech, Tempus AI, etc.
- Tempus AI: Deploying AI In Precision Medicine; Initiate With 'Buy'
- BioNTech: Clinical Hold Removal Pushes ADC Development Program Forward
- BioNTech Q2 Earnings Review: No Needle-Moving Catalysts Despite Oncology Promise
- Moderna, Pfizer updated mRNA COVID vaccines authorized by FDA
- Partial hold on BioNTech, MediLink cancer drug lifted by FDA
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
